Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06IDT
|
|||
| Former ID |
DAP000894
|
|||
| Drug Name |
Demecarium bromide
|
|||
| Synonyms |
Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Open-angle glaucoma [ICD-11: 9C61] | Approved | [1], [2] | |
| Therapeutic Class |
Parasympathomimetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H52Br2N4O4
|
|||
| Canonical SMILES |
CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-]
|
|||
| InChI |
1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2
|
|||
| InChIKey |
YHKBUDZECQDYBR-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 56-94-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7847733, 8153708, 15459655, 29224988, 49868409, 57323086, 80512977, 92719450, 99298841, 99319079, 103770497, 103825402, 104310746, 117369893, 121363189, 126628220, 126651359, 126667083, 134338171, 134970535, 137156545, 152036090, 160964283, 162173152, 175267303, 175611934, 184545801, 196109763, 223674083, 226420779, 241101997, 252347908, 252403278
|
|||
| ChEBI ID |
CHEBI:4391
|
|||
| SuperDrug ATC ID |
S01EB04
|
|||
| SuperDrug CAS ID |
cas=000056940
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Demecarium bromide (adjusted p-values: 2.08E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acetylcholinesterase (AChE) | Target Info | Inhibitor | [4], [5] |
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Cholinergic synapse | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| Pathwhiz Pathway | Phospholipid Biosynthesis | |||
| Pathway Interaction Database | ATF-2 transcription factor network | |||
| WikiPathways | Monoamine Transport | |||
| Biogenic Amine Synthesis | ||||
| Acetylcholine Synthesis | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011860. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. | |||
| REF 5 | Neuromuscular blocking agents and axial teratogenesis in the avian embryo. Can axial morphogenetic disorders by explained by pharmacological action upon muscle tissue Teratology. 1981 Apr;23(2):259-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.